Fingolimod, an immune modulating drug used to treat MS, decreases astroglial activation and NO production in response to sphingosine-1-phosphate (S1P), IL-1β and IL-17 (Colombo et al., 2014). This evidence concerns the gene IL1B and myeloid sarcoma.